Search research articles
Contact Us
Filters
Showing results (71-80 of 82) with videos related to
Page
of 9
Sort By:
The Lancet. Infectious Diseases
|
November 2, 2023
Diagnostic accuracy of a three-gene Mycobacterium tuberculosis host response cartridge using fingerstick blood for childhood tuberculosis: a multicentre prospective study in low-income and middle-income countries
Laura Olbrich, Valsan P Verghese, Zoe Franckling-Smith, et al.
BMJ Open
|
September 18, 2025
Evaluating the diagnostic accuracy of WHO-recommended treatment decision algorithms for childhood tuberculosis using an individual person dataset: a study protocol
Laura Olbrich, Leyla Larsson, P J Dodd, et al.
The Lancet. Infectious Diseases
|
September 23, 2024
Sequential and parallel testing for microbiological confirmation of tuberculosis disease in children in five low-income and middle-income countries: a secondary analysis of the RaPaed-TB study
Laura Olbrich, Zoe Franckling-Smith, Leyla Larsson, et al.
Thorax
|
May 2, 2020
Tuberculosis bacillary load, an early marker of disease severity: the utility of tuberculosis Molecular Bacterial Load Assay
Wilber Sabiiti, Khalide Azam, Eoghan Charles William Farmer, et al.
Plos Medicine
|
November 18, 2025
Diagnostic accuracy of the WHO tuberculosis treatment decision algorithms for children with presumptive tuberculosis: An individual participant data meta-analysis
Laura Olbrich, Leyla Larsson, Rory Dunbar, et al.
The Journal of Antimicrobial Chemotherapy
|
July 4, 2025
Cardiac safety of bedaquiline, delamanid and moxifloxacin co-administered with or without varying doses of sutezolid or delpazolid for the treatment of drug-susceptible TB
Simon E Koele, Krista Stoycheva, Cyprian Mtweve, et al.
BMC Genomics
|
August 5, 2022
Phylogenetic lineages of tuberculosis isolates and their association with patient demographics in Tanzania
Beatrice Kemilembe Mutayoba, Michael Hoelscher, Norbert Heinrich, et al.
The Lancet. Infectious Diseases
|
July 11, 2025
Sutezolid in combination with bedaquiline, delamanid, and moxifloxacin for pulmonary tuberculosis (PanACEA-SUDOCU-01): a prospective, open-label, randomised, phase 2b dose-finding trial
Norbert Heinrich, Christina Manyama, Simon E Koele, et al.
The Lancet. Infectious Diseases
|
July 11, 2025
Delpazolid in combination with bedaquiline, delamanid, and moxifloxacin for pulmonary tuberculosis (PanACEA-DECODE-01): a prospective, randomised, open-label, phase 2b, dose-finding trial
Lilian Tina Minja, Isabella van der Feltz, Christina Manyama, et al.
The Lancet. Infectious Diseases
|
January 20, 2017
High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial
Martin J Boeree, Norbert Heinrich, Rob Aarnoutse, et al.
Page
of 9
Search research articles
Search
Showing results (71-80 of 82) with videos related to
Sort By:
Page
of 9
The Lancet. Infectious Diseases
|
November 2, 2023
Diagnostic accuracy of a three-gene Mycobacterium tuberculosis host response cartridge using fingerstick blood for childhood tuberculosis: a multicentre prospective study in low-income and middle-income countries
Laura Olbrich, Valsan P Verghese, Zoe Franckling-Smith, et al.
BMJ Open
|
September 18, 2025
Evaluating the diagnostic accuracy of WHO-recommended treatment decision algorithms for childhood tuberculosis using an individual person dataset: a study protocol
Laura Olbrich, Leyla Larsson, P J Dodd, et al.
The Lancet. Infectious Diseases
|
September 23, 2024
Sequential and parallel testing for microbiological confirmation of tuberculosis disease in children in five low-income and middle-income countries: a secondary analysis of the RaPaed-TB study
Laura Olbrich, Zoe Franckling-Smith, Leyla Larsson, et al.
Thorax
|
May 2, 2020
Tuberculosis bacillary load, an early marker of disease severity: the utility of tuberculosis Molecular Bacterial Load Assay
Wilber Sabiiti, Khalide Azam, Eoghan Charles William Farmer, et al.
Plos Medicine
|
November 18, 2025
Diagnostic accuracy of the WHO tuberculosis treatment decision algorithms for children with presumptive tuberculosis: An individual participant data meta-analysis
Laura Olbrich, Leyla Larsson, Rory Dunbar, et al.
The Journal of Antimicrobial Chemotherapy
|
July 4, 2025
Cardiac safety of bedaquiline, delamanid and moxifloxacin co-administered with or without varying doses of sutezolid or delpazolid for the treatment of drug-susceptible TB
Simon E Koele, Krista Stoycheva, Cyprian Mtweve, et al.
BMC Genomics
|
August 5, 2022
Phylogenetic lineages of tuberculosis isolates and their association with patient demographics in Tanzania
Beatrice Kemilembe Mutayoba, Michael Hoelscher, Norbert Heinrich, et al.
The Lancet. Infectious Diseases
|
July 11, 2025
Sutezolid in combination with bedaquiline, delamanid, and moxifloxacin for pulmonary tuberculosis (PanACEA-SUDOCU-01): a prospective, open-label, randomised, phase 2b dose-finding trial
Norbert Heinrich, Christina Manyama, Simon E Koele, et al.
The Lancet. Infectious Diseases
|
July 11, 2025
Delpazolid in combination with bedaquiline, delamanid, and moxifloxacin for pulmonary tuberculosis (PanACEA-DECODE-01): a prospective, randomised, open-label, phase 2b, dose-finding trial
Lilian Tina Minja, Isabella van der Feltz, Christina Manyama, et al.
The Lancet. Infectious Diseases
|
January 20, 2017
High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial
Martin J Boeree, Norbert Heinrich, Rob Aarnoutse, et al.
Page
of 9